DOCSLIB.ORG

Identification of Novel Biomarkers and Candidate Small Molecule Drugs in Non-Small-Cell Lung Cancer by Integrated Microarray Analysis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Identification of Novel Biomarkers and Candidate Small Molecule Drugs in Non-Small-Cell Lung Cancer by Integrated Microarray Analysis OncoTargets and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Identification of novel biomarkers and candidate small molecule drugs in non-small-cell lung cancer by integrated microarray analysis This article was published in the following Dove Press journal: OncoTargets and Therapy Qiong Wu1,2,* Background: Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer Bo Zhang1,2,* morbidity and mortality worldwide. In the present study, we identified novel biomarkers Yidan Sun3 associated with the pathogenesis of NSCLC aiming to provide new diagnostic and therapeu- Ran Xu1 tic approaches for NSCLC. Xinyi Hu4 Methods: The microarray datasets of GSE18842, GSE30219, GSE31210, GSE32863 and Shiqi Ren4 GSE40791 from Gene Expression Omnibus database were downloaded. The differential Qianqian Ma5 expressed genes (DEGs) between NSCLC and normal samples were identified by limma Chen Chen6 package. The construction of protein–protein interaction (PPI) network, module analysis and Jian Shu7 enrichment analysis were performed using bioinformatics tools. The expression and prog- Fuwei Qi7 nostic values of hub genes were validated by GEPIA database and real-time quantitative fi Ting He7 PCR. Based on these DEGs, the candidate small molecules for NSCLC were identi ed by the CMap database. Wei Wang2 Results: A total of 408 overlapping DEGs including 109 up-regulated and 296 down- Ziheng Wang2 regulated genes were identified; 300 nodes and 1283 interactions were obtained from the 1 Medical School of Nantong University, PPI network. The most significant biological process and pathway enrichment of DEGs were Nantong 226001, People’s Republic of China; 2The Hand Surgery Research Center, response to wounding and cell adhesion molecules, respectively. Six DEGs (PTTG1, TYMS, Department of Hand Surgery, Affiliated ECT2, COL1A1, SPP1 and CDCA5) which significantly up-regulated in NSCLC tissues, Hospital of Nantong University, Nantong 226001, People’s Republic of China; were selected as hub genes according to the results of module analysis. The GEPIA database 3Department of Oncology, First Teaching further confirmed that patients with higher expression levels of these hub genes experienced Hospital of Tianjin University of Traditional fi Chinese Medicine, Tianjin 300193, People’s a shorter overall survival. Additionally, CMap predicted the 20 most signi cant small Republic of China; 4Department of molecules as potential therapeutic drugs for NSCLC. DL-thiorphan was the most promising Biochemistry & Molecular Biology, Nantong small molecule to reverse the NSCLC gene expression. University, Nantong, Jiangsu 226001, People’s Republic of China; 5Emergency Office, Wuxi Conclusions: Based on the gene expression profiles of 696 NSCLC samples and 237 Center for Disease Control and Prevention, normal samples, we first revealed that PTTG1, TYMS, ECT2, COL1A1, SPP1 and Wuxi 214023, People’s Republic of China; 6Department of Oncology, The Affiliated CDCA5 could act as the promising novel diagnostic and therapeutic targets for NSCLC. Cancer Hospital of Nanjing Medical University, Our work will contribute to clarifying the molecular mechanisms of NSCLC initiation and Nanjing, People’s Republic of China; 7The First People‘s Hospital of Taicang City, Taicang progression. Affiliated Hospital of Soochow University, Keywords: non-small-cell lung cancer, novel biomarkers, candidate small molecules, Suzhou 215400, People’sRepublicofChina prognosis, bioinformatics analysis *These authors contributed equally to this work Correspondence: Ziheng Wang; Wei Wang The Hand Surgery Research Center, Introduction Department of Hand Surgery, Affiliated Lung cancer remains the leading cause of cancer morbidity and mortality worldwide. In Hospital of Nantong University, Nantong 226001, People’s Republic of China 2018, there are 234,030 newly diagnosed lung cancer patients, accounting for 13.5% of Tel +86 159 6297 0534; +86 136 1521 3504 all types of malignant tumors. In addition, lung cancer results in approximately 154,050 Email [email protected]; [email protected] death cases each year, accounting for 25.3% of all cancer-related deaths; 80–85% of all submit your manuscript | www.dovepress.com OncoTargets and Therapy 2019:12 3545–3563 3545 DovePress © 2019 Wu et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work http://doi.org/10.2147/OTT.S198621 you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Wu et al Dovepress lung cancer patients are diagnosed with non-small-cell lung basedonGPL9948(AgilentHuman0.6KmiRNA cancer (NSCLC) subtype and 80% lung cancer-associated Microarray G4471A; Agilent Technologies, Santa Clara, deaths are caused by NSCLC. The subtypes of NSCLC CA, USA) (GSE32863) and GPL570 (Affymetrix Human mainly consist of lung adenocarcinoma, lung squamous cell Genome U113 Plus 2.0 Array) (GSE18842, GSE30219, carcinoma and large cell lung cancer based on histological GSE31210 and GSE40791). A total of 696 NSCLC samples sub-classification.1–4 Although great advance has been made and 237 normal samples were included in our study, of which in the therapeutic methods for NSCLC such as surgical 46 tumor samples and 45 normal samples were in GSE18842 resection, chemotherapy, radiotherapy and targeted therapy, profile, 272 tumor samples and 14 normal samples in the patients’ prognosis is still far from ideal, with 5-year GSE30219 profile, 226 tumor samples and 20 normal samples survival rate less than 20%. For advanced patients who are in GSE31210 profile, 58 tumor samples and 58 normal sam- inoperable, chemotherapy such as platinum still remains the ples in GSE32863 profile, and 94 tumor samples and 100 most ideal and important treatment strategy for NSCLC.5–7 normal samples in GSE40791 profile. The poor long-term survival rate of NSCLC patients is mainly attributed to the lack of specific symptoms and effec- Screeningfor DEGs tive diagnostic methods at an early stage. In additionally, The matrix data of each dataset was performed log2 con- high metastasis rate and drug resistance are also vital factors version and normalization using limma package of R/ 8–10 that can not be ignored. In recent years, with our Bioconductor software.14 The limma package was also increased understanding of molecular characterization of utilized to screen and identify the DEGs between NSCLC, molecular targeting therapies especially individua- NSCLC samples and normal tissue sample. Adjust P- lized precision treatment have undergone remarkable value <0.05 and |log2FC| >1 were considered the statistical 11,12 developments. Despite the prominent progress in the significance of differential expression. molecular diagnosis and treatment for NSCLC, substantive 13 breakthroughs have not yet been made in patients’ survival. Functional enrichment analysis Therefore, there is still an urgent demand to identify the GO and Kyoto Encyclopedia of Genes and Genomes novel biomarkers correlated with NSCLC diagnosis and (KEGG) pathway enrichment analysis were performed to prognosis to elucidate the precise molecular mechanism of determine the biological functions of the overlapping NSCLC occurrence and progression. In this study, the micro- DEGs. GO enrichment analysis is an extensively used array data of GSE18842, GSE30219, GSE31210, GSE32863 method to investigate the molecular function (MF), cell and GSE40791 from Gene Expression Omnibus (GEO) data- component (CC) and biological process (BP) of genes or base was used to identify the differential expressed genes gene products. KEGG is a widely used database for systema- (DEGs) between NSCLC and adjacent normal tissues. Gene tic analysis of high-level gene functions. In this study, we Ontology (GO) and pathway enrichment analysis were per- carried out GO function and KEGG pathway enrichment formed to better understand the biological functions of these analysis based on the platform of Database for Annotation DEGs. We also established a protein–protein interaction Visualization and Integrated Discovery (DAVID, http:// (PPI) network associated the DEGs. Furthermore, we also david.ncifcrf.gov), an online database rich in comprehensive identified potential candidate small molecules for a better annotation information of gene and protein functions. P- treatment of NSCLC. Six novel biomarkers were found to – value <0.05 was considered statistically significant.15 19 be related to the pathogenesis and prognosis of NSCLC. In summary, this study aimed to exploit promising novel bio- – markers for NSCLC diagnosis, prognosis and molecular Protein protein interaction (PPI) targeting therapies from new insights. Figure 1 shows the network construction and module workflow of our study. analysis We used the online database STRING (Search Tool for the Materials and methods Retrieval of Interacting Genes, https://string-db.org/) to better Data resources illustrate the potential interactive relationships among the Series matrix files of GSE18842, GSE30219, GSE31210, overlapping DEGs.20 Then the Cytoscape
Load more

Recommended publications
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
    [Show full text]
  • Rabbit Anti-CDCA5/FITC Conjugated Antibody
    SunLong Biotech Co.,LTD Tel: 0086-571- 56623320 Fax:0086-571- 56623318 E-mail:[email protected] www.sunlongbiotech.com Rabbit Anti-CDCA5/FITC Conjugated antibody SL7717R-FITC Product Name: Anti-CDCA5/FITC Chinese Name: FITC标记的细胞分裂周期相关蛋白5抗体 Alias: Cell division cycle associated protein 5; MGC16386; p35; Sororin; CDCA5_HUMAN. Organism Species: Rabbit Clonality: Polyclonal React Species: Human,Mouse,Rat,Dog,Pig,Cow,Horse,Rabbit, Flow-Cyt=1:50-200IF=1:50-200 Applications: not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. Molecular weight: 28kDa Form: Lyophilized or Liquid Concentration: 1mg/ml immunogen: KLH conjugated synthetic peptide derived from human CDCA5 Lsotype: IgG Purification: affinity purified by Protein A Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibodywww.sunlongbiotech.com is stable at room temperature for at least one month and for greater than a year Storage: when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. background: Sororin, also designated cell division cycle-associated protein 5 (CDCA5) or p35, functions as a regulator of sister chromatid cohesion during mitosis. It interacts with the APC/C complex and is found in a complex consisting of cohesion components SCC- 112, MC1L1, SMC3L1, RAD21 and APRIN. The deduced human and mouse Sororin Product Detail: proteins consist of 252 and 264 amino acid residues, respectively, and both contain a KEN box for APC-dependent ubiquitination.
    [Show full text]
  • Investigation of the Underlying Hub Genes and Molexular Pathogensis in Gastric Cancer by Integrated Bioinformatic Analyses
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.20.423656; this version posted December 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Investigation of the underlying hub genes and molexular pathogensis in gastric cancer by integrated bioinformatic analyses Basavaraj Vastrad1, Chanabasayya Vastrad*2 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India bioRxiv preprint doi: https://doi.org/10.1101/2020.12.20.423656; this version posted December 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract The high mortality rate of gastric cancer (GC) is in part due to the absence of initial disclosure of its biomarkers. The recognition of important genes associated in GC is therefore recommended to advance clinical prognosis, diagnosis and and treatment outcomes. The current investigation used the microarray dataset GSE113255 RNA seq data from the Gene Expression Omnibus database to diagnose differentially expressed genes (DEGs). Pathway and gene ontology enrichment analyses were performed, and a proteinprotein interaction network, modules, target genes - miRNA regulatory network and target genes - TF regulatory network were constructed and analyzed. Finally, validation of hub genes was performed. The 1008 DEGs identified consisted of 505 up regulated genes and 503 down regulated genes.
    [Show full text]
  • Supplementary Data
    SUPPLEMENTARY DATA A cyclin D1-dependent transcriptional program predicts clinical outcome in mantle cell lymphoma Santiago Demajo et al. 1 SUPPLEMENTARY DATA INDEX Supplementary Methods p. 3 Supplementary References p. 8 Supplementary Tables (S1 to S5) p. 9 Supplementary Figures (S1 to S15) p. 17 2 SUPPLEMENTARY METHODS Western blot, immunoprecipitation, and qRT-PCR Western blot (WB) analysis was performed as previously described (1), using cyclin D1 (Santa Cruz Biotechnology, sc-753, RRID:AB_2070433) and tubulin (Sigma-Aldrich, T5168, RRID:AB_477579) antibodies. Co-immunoprecipitation assays were performed as described before (2), using cyclin D1 antibody (Santa Cruz Biotechnology, sc-8396, RRID:AB_627344) or control IgG (Santa Cruz Biotechnology, sc-2025, RRID:AB_737182) followed by protein G- magnetic beads (Invitrogen) incubation and elution with Glycine 100mM pH=2.5. Co-IP experiments were performed within five weeks after cell thawing. Cyclin D1 (Santa Cruz Biotechnology, sc-753), E2F4 (Bethyl, A302-134A, RRID:AB_1720353), FOXM1 (Santa Cruz Biotechnology, sc-502, RRID:AB_631523), and CBP (Santa Cruz Biotechnology, sc-7300, RRID:AB_626817) antibodies were used for WB detection. In figure 1A and supplementary figure S2A, the same blot was probed with cyclin D1 and tubulin antibodies by cutting the membrane. In figure 2H, cyclin D1 and CBP blots correspond to the same membrane while E2F4 and FOXM1 blots correspond to an independent membrane. Image acquisition was performed with ImageQuant LAS 4000 mini (GE Healthcare). Image processing and quantification were performed with Multi Gauge software (Fujifilm). For qRT-PCR analysis, cDNA was generated from 1 µg RNA with qScript cDNA Synthesis kit (Quantabio). qRT–PCR reaction was performed using SYBR green (Roche).
    [Show full text]
  • Early Growth Response 1 Regulates Hematopoietic Support and Proliferation in Human Primary Bone Marrow Stromal Cells
    Hematopoiesis SUPPLEMENTARY APPENDIX Early growth response 1 regulates hematopoietic support and proliferation in human primary bone marrow stromal cells Hongzhe Li, 1,2 Hooi-Ching Lim, 1,2 Dimitra Zacharaki, 1,2 Xiaojie Xian, 2,3 Keane J.G. Kenswil, 4 Sandro Bräunig, 1,2 Marc H.G.P. Raaijmakers, 4 Niels-Bjarne Woods, 2,3 Jenny Hansson, 1,2 and Stefan Scheding 1,2,5 1Division of Molecular Hematology, Department of Laboratory Medicine, Lund University, Lund, Sweden; 2Lund Stem Cell Center, Depart - ment of Laboratory Medicine, Lund University, Lund, Sweden; 3Division of Molecular Medicine and Gene Therapy, Department of Labora - tory Medicine, Lund University, Lund, Sweden; 4Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands and 5Department of Hematology, Skåne University Hospital Lund, Skåne, Sweden ©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2019.216648 Received: January 14, 2019. Accepted: July 19, 2019. Pre-published: August 1, 2019. Correspondence: STEFAN SCHEDING - [email protected] Li et al.: Supplemental data 1. Supplemental Materials and Methods BM-MNC isolation Bone marrow mononuclear cells (BM-MNC) from BM aspiration samples were isolated by density gradient centrifugation (LSM 1077 Lymphocyte, PAA, Pasching, Austria) either with or without prior incubation with RosetteSep Human Mesenchymal Stem Cell Enrichment Cocktail (STEMCELL Technologies, Vancouver, Canada) for lineage depletion (CD3, CD14, CD19, CD38, CD66b, glycophorin A). BM-MNCs from fetal long bones and adult hip bones were isolated as reported previously 1 by gently crushing bones (femora, tibiae, fibulae, humeri, radii and ulna) in PBS+0.5% FCS subsequent passing of the cell suspension through a 40-µm filter.
    [Show full text]
  • Temporal Proteomic Analysis of HIV Infection Reveals Remodelling of The
    1 1 Temporal proteomic analysis of HIV infection reveals 2 remodelling of the host phosphoproteome 3 by lentiviral Vif variants 4 5 Edward JD Greenwood 1,2,*, Nicholas J Matheson1,2,*, Kim Wals1, Dick JH van den Boomen1, 6 Robin Antrobus1, James C Williamson1, Paul J Lehner1,* 7 1. Cambridge Institute for Medical Research, Department of Medicine, University of 8 Cambridge, Cambridge, CB2 0XY, UK. 9 2. These authors contributed equally to this work. 10 *Correspondence: [email protected]; [email protected]; [email protected] 11 12 Abstract 13 Viruses manipulate host factors to enhance their replication and evade cellular restriction. 14 We used multiplex tandem mass tag (TMT)-based whole cell proteomics to perform a 15 comprehensive time course analysis of >6,500 viral and cellular proteins during HIV 16 infection. To enable specific functional predictions, we categorized cellular proteins regulated 17 by HIV according to their patterns of temporal expression. We focussed on proteins depleted 18 with similar kinetics to APOBEC3C, and found the viral accessory protein Vif to be 19 necessary and sufficient for CUL5-dependent proteasomal degradation of all members of the 20 B56 family of regulatory subunits of the key cellular phosphatase PP2A (PPP2R5A-E). 21 Quantitative phosphoproteomic analysis of HIV-infected cells confirmed Vif-dependent 22 hyperphosphorylation of >200 cellular proteins, particularly substrates of the aurora kinases. 23 The ability of Vif to target PPP2R5 subunits is found in primate and non-primate lentiviral 2 24 lineages, and remodeling of the cellular phosphoproteome is therefore a second ancient and 25 conserved Vif function.
    [Show full text]
  • CDCA5 Promotes the Progression of Prostate Cancer by Affecting the ERK Signalling Pathway
    ONCOLOGY REPORTS 45: 921-932, 2021 CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway JUNPENG JI1,2*, TIANYU SHEN1,3*, YANG LI1*, YIXI LIU1, ZHIQUN SHANG1 and YUANJIE NIU1 1Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Hexi, Tianjin 300211; 2Department of Urology, The Third Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan 471003; 3School of Medicine, Nankai University, Tianjin 300071, P.R. China Received July 17, 2020; Accepted November 9, 2020 DOI: 10.3892/or.2021.7920 Abstract. Cell division cycle-associated 5 (CDCA5) can regu- expression inhibited PCa cell proliferation by inhibiting the late cell cycle-related proteins to promote the proliferation of ERK signalling pathway. Thus, CDCA5 may be a potential cancer cells. The purpose of the present study was to investigate therapeutic target for PCa. the expression level of CDCA5 in prostate cancer (PCa) and its effect on PCa progression. The signalling pathway by which Introduction CDCA5 functions through was also attempted to elucidate. Clinical specimens of PCa patients were collected from the Prostate cancer (PCa) is a genitourinary malignancy that Second Hospital of Tianjin Medical University. The expres- threatens the health of men worldwide. In Europe and the sion level of CDCA5 in cancer tissues and paracancerous United States, the incidence (19%) of PCa ranks first among tissues from PCa patients was detected by RT-qPCR analysis male malignant tumours, and its mortality (9%) ranks and IHC. The relationship between the expression level of second (1,2). Currently, the incidence of PCa in China has CDCA5 and the survival rate of PCa patients was analysed surpassed that of bladder cancer to rank first among male using TCGA database.
    [Show full text]
  • Pituitary Tumor Transforming Gene 1 Regulates Aurora Kinase a Activity
    Oncogene (2008) 27, 6385–6395 & 2008 Macmillan Publishers Limited All rights reserved 0950-9232/08 $32.00 www.nature.com/onc ORIGINAL ARTICLE Pituitary tumor transforming gene 1 regulates Aurora kinase A activity Y Tong, A Ben-Shlomo, C Zhou, K Wawrowsky and S Melmed Department of Medicine, Cedars-Sinai Research Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA Pituitary tumor transforming gene 1 (PTTG1),a pathogenesis of estrogen-induced rat prolactinomas transforming gene highly expressed in several cancers,is (Heaney et al., 1999), and has been suggested as a a mammalian securin protein regulating both G1/S and prognostic marker for thyroid, breast (Solbach et al., G2/M phases. Using protein array screening,we showed 2004)and colon cancer invasiveness (Heaney et al., PTTG1 interacting with Aurora kinase A (Aurora-A), 2000). PTTG and HTLV-1 Tax exhibit a cooperative and confirmed the interaction using co-immunoprecipita- transforming activity (Sheleg et al., 2007), whereas small tion,His-tagged pull-down assays and intracellular interfering RNA (siRNA)directed against PTTG immunofluorescence colocalization. PTTG1 transfection suppressed lung cancer growth in nude mice (Kakar into HCT116 cells prevented Aurora-A T288 autopho- and Malik, 2006)and was also proposed as a subcellular sphorylation,inhibited phosphorylation of the histone H3 therapy for ovarian cancer (El-Naggar et al., 2007). Aurora-A substrate and resulted in abnormally condensed Overexpressed PTTG1 results in chromosome chromatin. PTTG1-null cell proliferation was more instability and aneuploidy, which has been suggested sensitive to Aurora-A knock down and to Aurora kinase as a mechanism underlying PTTG1 transforming Inhibitor III treatment.
    [Show full text]
  • (PTTG1IP/PBF) Predicts Breast Cancer Survival
    Repo et al. BMC Cancer (2017) 17:705 DOI 10.1186/s12885-017-3694-6 RESEARCHARTICLE Open Access PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival Heli Repo1* , Natalia Gurvits1, Eliisa Löyttyniemi2, Marjukka Nykänen3, Minnamaija Lintunen1, Henna Karra4, Samu Kurki5, Teijo Kuopio3, Kati Talvinen1, Mirva Söderström1 and Pauliina Kronqvist1 Abstract Background: PTTG1-interacting protein (PTTG1IP) is an oncogenic protein, which participates in metaphase-anaphase transition of the cell cycle through activation of securin (PTTG1). PTTG1IP promotes the shift of securin from the cell cytoplasm to the nucleus, allowing the interaction between separase and securin. PTTG1IP overexpression has been previously observed in malignant disease, e.g. in breast carcinoma. However, the prognostic value of PTTG1IP in breast carcinoma patients has not previously been revealed. Methods: A total of 497 breast carcinoma patients with up to 22-year follow-up were analysed for PTTG1IP and securin immunoexpression. The results were evaluated for correlations with the clinical prognosticators and patient survival. Results: In our material, negative PTTG1IP immunoexpression predicted a 1.5-fold risk of breast cancer death (p =0.02). However, adding securin immunoexpression to the analysis indicated an even stronger and independent prognostic power in the patient material (HR = 2.5, p < 0.0001). The subcellular location of securin was found with potential prognostic value also among the triple-negative breast carcinomas (n = 96, p = 0.052). Conclusions: PTTG1IP-negativity alone and in combination with high securin immunoexpression indicates a high risk of breast cancer death, resulting in up to 14-year survival difference in our material. Keywords: PTTG1IP, PBF, Immunohistochemistry, Breast cancer, Prognosis Background nucleus, allowing the interaction between separase and Pituitary tumour transforming gene 1 interacting pro- securin [1].
    [Show full text]
  • Nuclear Localization of PTTG1 Promotes Migration and Invasion of Seminoma Tumor Through Activation of MMP-2
    Nuclear Localization of PTTG1 Promotes Migration and Invasion of Seminoma Tumor Through Activation of MMP-2. Emanuela Teveroni International Scientic Institute "Paul VI", ISI, Fondazione Policlinico "A.Gemelli" IRCCS Fiorella Di Nicuolo International Scientic Institute "Paul VI", ISI, Fondazione Policlinico "A.Gemelli" IRCCS Giada Bianchetti Department of Neuroscience, section of Biophysics, Università Cattolica del Sacro Cuore Alan L. Epstein Department of Pathology, Keck school of medicine, University of Southern California, Los Angeles Giuseppe Grande International Scientic Institute "Paul VI", ISI, Fondazione Policlinico "A.Gemelli" IRCCS Giuseppe Maulucci Department of Neuroscience, section of Biophysics, Università Cattolica del Sacro Cuore Marco De Spirito Università Cattolica del Sacro Cuore: Universita Cattolica del Sacro Cuore Alfredo Pontecorvi Division of Endocrinology, Fondazione policlinico "A.Gemelli" IRCCS Domenico Milardi Division of Endocrinology, Fondazione policlinico "A.Gemelli" IRCCS Francesca Mancini ( [email protected] ) International Scientic Institute "Paul VI", ISI, Fondazione Policlinico 'A. Gemelli' IRCCS, Rome, Italy https://orcid.org/0000-0002-2459-8815 Research Keywords: PTTG1, seminoma cell lines, testicular cancer, PBF, MMP-2, invasiveness Posted Date: December 15th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-125309/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/53 Abstract Background: Seminoma is the most common subtype of testicular germ cell tumors (TGCTs) and its molecular patterns have not been fully claried. The pituitary tumor-transforming gene 1 (PTTG1) is a securin, inhibitor of premature sister chromatid segregation during mitosis and is overexpressed in many cancers. PTTG1 shows the ability to sustain the invasiveness of several cancer types through its transcriptional activity.
    [Show full text]
  • Dissecting the DNA Binding Landscape and Gene Regulatory Network of P63 and P53
    bioRxiv preprint doi: https://doi.org/10.1101/2020.06.11.145540; this version posted June 12, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Dissecting the DNA binding landscape and gene regulatory network of p63 and p53 Konstantin Riege1, Helene Kretzmer2, Simon S. McDade3, Steve Hoffmann1, Martin Fischer1,# 1 Computational Biology Group, Leibniz Institute on Aging – Fritz Lipmann Institute (FLI), Beutenbergstraße 11, 07745 Jena, Germany 2 Department of Genome Regulation, Max Planck Institute for Molecular Genetics, Ihnestraße 63-73, 14195 Berlin, Germany 3 Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK Running title: p63 GRN vs p53 GRN #To whom correspondence should be addressed. Email: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2020.06.11.145540; this version posted June 12, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract The transcription factor (TF) p53 is the best-known tumor suppressor, but its ancient sibling p63 (ΔNp63) is a master regulator of epidermis development and a key oncogenic driver in squamous cell carcinomas (SCC). Despite multiple gene expression studies becoming available in recent years, the limited overlap of reported p63-dependent genes has made it difficult to decipher the p63 gene regulatory network (GRN).
    [Show full text]
  • Distinct Expression of CDCA3, CDCA5, and CDCA8 Leads to Shorter Relapse Free Survival in Breast Cancer Patient
    www.impactjournals.com/oncotarget/ Oncotarget, 2018, Vol. 9, (No. 6), pp: 6977-6992 Research Paper Distinct expression of CDCA3, CDCA5, and CDCA8 leads to shorter relapse free survival in breast cancer patient Nam Nhut Phan1,2,*, Chih-Yang Wang3,*, Kuan-Lun Li1, Chien-Fu Chen4, Chung- Chieh Chiao4, Han-Gang Yu5, Pung-Ling Huang1,6 and Yen-Chang Lin1 1Graduate Institute of Biotechnology, Chinese Culture University, Taipei, Taiwan 2NTT Institute of Hi-Technology, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam 3Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan 4School of Chinese Medicine for Post-Baccalaureate, I-Shou University, Kaohsiung, Taiwan 5Department of Physiology and Pharmacology, West Virginia University, Morgantown, WV, USA 6Department of Horticulture & Landscape Architecture, National Taiwan University, Taipei, Taiwan *These authors have contributed equally to this work Correspondence to: Pung-Ling Huang, email: [email protected] Yen-Chang Lin, email: [email protected] Keywords: cell cycle division-associated (CDCA) protein; breast cancer; cell cycle; prognosis; bioinformatics Received: October 16, 2017 Accepted: January 03, 2018 Published: January 09, 2018 Copyright: Phan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Breast cancer is a dangerous disease that results in high mortality rates for cancer patients. Many methods have been developed for the treatment and prevention of this disease. Determining the expression patterns of certain target genes in specific subtypes of breast cancer is important for developing new therapies for breast cancer.
    [Show full text]